Indeed, we did not confirm a statistical enrichment for Bim expression in HER2 overexpressing cancers by our gene-matching approach involving 5 cohorts (described above), even though enrichment for BID and BIK and impoverishment for BAD and NOXA were confirmed. The gene discussed is ERBB2; the disease is cancer.